StandardX has launched with £10m of seed funding co-led by Vsquared Ventures and East X Ventures, with firstminute capital, UKI2S, Brevan Howard Macro Venture and Geometry joining the round. The London company plans to supply its first isotopes to a medical research partner in 2027 and reach industrial-scale production by 2029.
Founded in 2025 by chief executive Richard Pearson and chief technology officer Ross Allen, both nuclear engineers, StandardX is building an accelerator-based refinery intended to produce a broad portfolio of isotopes from a single industrial footprint.
The existing supply chain is the opportunity the founders are selling. Isotopes used in cancer diagnostics and therapy are made today in ageing reactors and in cyclotrons configured for one product at a time, which leaves hospitals exposed to single points of failure. StandardX is pitching a system that can switch between isotopes rather than being purpose-built for each.
Terms beyond the headline figure were not disclosed. Neither the post-money valuation nor the split between the two co-leads has been published, and no information has been released on founder or employee ownership after the round.
The £10m is unusually large for a British pre-product deep-tech seed, and the investor list explains part of the structure. Vsquared Ventures, the Munich firm behind Isar Aerospace and The Exploration Company, and East X Ventures co-led; firstminute capital and Brevan Howard Macro Venture add London balance-sheet depth, while UKI2S — the government-backed seed fund managed for public research bodies — brings the state into the cap table at first institutional round.
Proceeds go on headcount and a site. StandardX intends to grow to more than 15 scientists and engineers and to secure an industrial location in London for its first refinery system.
The demand case rests on two markets moving at different speeds. New cancer cases are projected to rise 67% by 2050, and NHS performance is already strained: 69.6% of patients began treatment within 62 days in May 2026, against an 85% target. The second market is fusion, where tritium supply is the binding constraint — roughly 25kg exists worldwide, while a single commercial plant would consume tens of kilogrammes a year.
"Isotopes underpin the next era of innovation," Pearson said, arguing that medical and fusion applications "all share the same constraints around supply".
The 2027 milestone is the one investors will price off. Medical supply arrives first and generates revenue against an existing procurement market; fusion contracts remain forward-dated against reactors that are not yet built.
Original source: Tech Funding News — https://techfundingnews.com/standardx-10m-seed-isotope-refinery-cancer-fusion/
